MYC and hepatocellular carcinoma: Knocking out miR-122 in mice resulted in steatohepatitis and HCC with profound alterations of a plethora of genes regulating lipid metabolism, inflammation and fibrosis, and the AAV-mediated delivery of miR-122 markedly inhibited Myc-driven HCC in mice, thereby establishing both the tumor suppressor function of miR-122 and its therapeutic utility [82,83].